{"schema_version":"secwatch.filing_event.v1","accession":"0000899923-24-000036","form_type":"8-K","ticker":"MYGN","cik":"0000899923","company_name":"MYRIAD GENETICS INC","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.243329+00:00","generated_at":"2026-05-31T12:52:13.962122+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Myriad Genetics Q2 revenue $212M (+15% YoY); raises FY2024 guidance, adjusted EPS $0.05","bullets":["Revenue $212M (+15% YoY); GAAP EPS $(0.41) vs $(1.42) YoY; adjusted EPS $0.05 vs $(0.08).","Raises FY2024 revenue guidance to $835-$845M (11-12% growth); adj EPS to $0.08-$0.12.","Prenatal rev +25%, Pharmacogenomics +22%, Hereditary Cancer +19%; Tumor profiling -9% YoY.","Cross-license with Personalis (PSNL) for MRD patents; GSK collaboration for HRD testing.","Long-term revenue growth target raised to 12% from prior; total test volume +9% to 389K."],"urls":{"canonical":"https://secwatch.observer/filing/0000899923-24-000036","json":"https://secwatch.observer/filing/0000899923-24-000036.json","markdown":"https://secwatch.observer/filing/0000899923-24-000036.md","text":"https://secwatch.observer/filing/0000899923-24-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899923/000089992324000036/0000899923-24-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899923/000089992324000036/mygn-20240806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:52:13.962122+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}